Biovitrum to Acquire Kepivance® and Stemgen® and Exclusively License Kineret® from Amgen

STOCKHOLM, Sweden and THOUSAND OAKS, California, USA - September  15,
2008.   Biovitrum  AB  (publ)   (STO:BVT)  and  Amgen   (NASDAQ:AMGN)
announced today that they have entered into an agreement under  which
Biovitrum will  acquire the  marketed biologic  therapeutic  products
 Kepivance®  (palifermin) and  Stemgen®  (ancestim)  from Amgen,  and
will also obtain from Amgen a worldwide exclusive license to Kineret®
(anakinra) for  its  current  approved  indication.    The  agreement
includes an inventory of the three products at an undisclosed value.

Kineret, Kepivance and Stemgen generated combined sales of nearly $70
million in 2007.

The financial terms of the transaction include an upfront payment  of
approximately $130 million,  consisting of $110  million in cash  and
ordinary shares of Biovitrum, representing a value of $20 million  at
the time of closing, subject  to certain adjustments provided in  the
acquisition agreement. In  addition, the agreement  provides for  the
payment of sales milestones and additional contingent payments  under
certain  circumstances,  including,  without  limitation,   potential
royalties in  the event  that Biovitrum  develops modified  forms  of
Kineret. Biovitrum will finance the  cash portion of the  transaction
with debt and existing cash. The transaction is expected to close  by
the end of 2008."The acquisition  of  these exciting  biotechnology  therapeutics  is
fully in line with our business  strategy and roadmap for growth   We
will now  expand  Biovitrum's  presence  to  include  North  America,
Europe, Australia  and New  Zealand, which  will enable  us to  serve
patients with  unmet medical  needs in  these regions,"  said  Martin
Nicklasson, CEO of  Biovitrum. "Moreover, the  new products will  add
valuable momentum to our top  line performance as well as  additional
cash flow. The successful agreement is also a validation of our  good
and strong relationship with Amgen," Nicklasson added."We are  pleased  that Biovitrum,  a  trusted business  partner,  has
agreed to take  on these  important medicines and  plans to  continue
making them  available to  the patients  who need  them," said  Kevin
Sharer, Amgen Chairman and CEO, "This deal will allow Amgen to  focus
its resources  on developing  new, innovative  therapies for  serious
illnesses, and  on  expanding  its  core  products  to  benefit  more
patients in markets around the world," Sharer added.

About Kineret® (anakinra)
Information about Kineret® can be found at the following Amgen site:
http://www.amgen.com/patients/products_kineret.html
Healthcare professionals  should  refer  to and  rely  upon  the  PDR
(Physician's Desk Reference) or  the corresponding national  labeling
texts, and not the information at the Amgen site.

About Kepivance® (palifermin)
Information about  Kepivance® can  be found  at the  following  Amgen
site:
http://www.amgen.com/patients/products_kepivance.html
Healthcare professionals  should  refer  to and  rely  upon  the  PDR
(Physician's Desk Reference) or  the corresponding national  labeling
texts, and not the information at the Amgen site.

About Stemgen® (ancestim)
Information about Stemgen® can be found at the following Amgen site:
http://www.amgen.com.au/patients/products_enbrel.html
Healthcare professionals should refer to national labeling texts, and
not the information at the Amgen site.

About Biovitrum
Biovitrum is a pharmaceutical company  with operations in Sweden  and
in the UK. The company markets a range of specialist  pharmaceuticals
primarily in the Nordic countries. Using its expertise and experience
Biovitrum takes scientific innovation all  the way to the market  and
to specialist  indication  patients with  significant  medical  need.
Research  expertise   and   capabilities  include   development   and
production of biotechnology therapeutics,  as well as small  molecule
discovery and  development. With  revenues of  approximately SEK  1.3
billion and around 500 employees, Biovitrum is a significant European
specialty pharmaceutical  player.  It is  listed  on the  OMX  Nordic
Exchange in Stockholm. For more information go to www.biovitrum.com

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology  pioneer since 1980,  Amgen was one  of
the first companies to realize the new science's promise by  bringing
safe and effective  medicines from  lab, to  manufacturing plant,  to
patient. Amgen therapeutics  have changed the  practice of  medicine,
helping millions  of people  around the  world in  the fight  against
cancer, kidney  disease,  rheumatoid  arthritis,  and  other  serious
illnesses. With a deep and broad pipeline of potential new medicines,
Amgen remains committed to advancing science to dramatically  improve
people's lives. To learn  more about our  pioneering science and  our
vital medicines, visit www.amgen.com


Forward looking statement: Biovitrum
Statements  included  herein  that  are  not  historical  facts   are
forward-looking statements. Such forward-looking statements involve a
number of risks and  uncertainties and are subject  to change at  any
time.  In  the  event   such  risks  or  uncertainties   materialize,
Biovitrum's results  could  be  materially affected.  The  risks  and
uncertainties include, but are not limited to, risks associated  with
the inherent  uncertainty  of  pharmaceutical  research  and  product
development,  manufacturing  and  commercialization,  the  impact  of
competitive   products,   patents,   legal   challenges,   government
regulation and approval, Biovitrum's  ability to secure new  products
for  commercialization  and/or  development   and  other  risks   and
uncertainties detailed from time to time in Biovitrum AB's interim or
annual reports, prospectuses or press releases.

Forward looking statement: Amgen
This news release  contains forward-looking  statements that  involve
significant risks and uncertainties, including those discussed  below
and others that can be found in Amgen's Form 10-K for the year  ended
December 31, 2007, and in its periodic reports on Form 10-Q and  Form
8-K.  Amgen is providing this information as of the date of this news
release  and  does  not  undertake  any  obligation  to  update   any
forward-looking statements contained in this document as a result  of
new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may
differ materially from those Amgen projects.  Amgen's results may  be
affected by  Amgen's  ability to  successfully  market both  new  and
existing products  domestically  and  internationally,  clinical  and
regulatory developments (domestic or  foreign) involving current  and
future  products,  sales  growth   of  recently  launched   products,
competition from other products  (domestic or foreign),  difficulties
or delays in manufacturing its products.  In addition, sales of Amgen
products  are   affected  by   reimbursement  policies   imposed   by
third-party payors,  including governments,  private insurance  plans
and managed  care  providers  and  may  be  affected  by  regulatory,
clinical and guideline  developments and  domestic and  international
trends toward managed care and healthcare cost containment as well as
U.S. legislation affecting pharmaceutical pricing and reimbursement.
Government and  others' regulations  and reimbursement  policies  may
affect  the  development,  usage  and  pricing  of  Amgen  products.
Furthermore, Amgen's research, testing, pricing, marketing and  other
operations are  subject  to  extensive  regulation  by  domestic  and
foreign government  regulatory authorities.   Amgen or  others  could
identify safety, side  effects or manufacturing  problems with  Amgen
products after  they are  on  the market.   Amgen's business  may  be
impacted  by  government  investigations,  litigation  and   products
liability claims.  Further, while Amgen routinely obtains patents for
its products and  technology, the protection  offered by its  patents
and  patent   applications   may  be   challenged,   invalidated   or
circumvented by its competitors.  Amgen depends on third parties  for
a significant portion of its manufacturing capacity for the supply of
certain of its current and future  products and limits on supply  may
constrain sales  of  certain  of its  current  products  and  product
candidate  development.   In  addition,  Amgen  competes  with  other
companies with respect to  some of its marketed  products as well  as
for the  discovery and  development of  new products.   Discovery  or
identification of  new product  candidates cannot  be guaranteed  and
movement from concept  to product is  uncertain; consequently,  there
can be no  guarantee that  any particular product  candidate will  be
successful and  become  a  commercial  product.   Further,  some  raw
materials, medical devices and component parts for Amgen products are
supplied by sole third-party suppliers.

For more information please contact:
Biovitrum
Martin Nicklasson, CEO
Phone: +46 8 697 2545

Göran Arvidson, CFO
Cell phone: +46 70 633 30 42

Erik Kinnman, VP Investor Relations
Cell phone: +46 73 422 15 40
erik.kinnman@biovitrum.com

Amgen, Thousand Oaks
Mary Klem (Media, U.S.)
Phone: +1 805 447 6979
Mobile: +1 805  341 0687

Arvind Sood (Investors)
Phone: +1 805 447 1060